Stifel initiated coverage on Asensus Surgical with a new price target
$ASXC
Medical/Dental Instruments
Health Care
Stifel initiated coverage of Asensus Surgical with a rating of Buy and set a new price target of $1.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 9/8/2022 | $1.50 | Overweight | Cantor Fitzgerald |
| 9/8/2022 | $1.50 | Buy | Stifel |
15-12G - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
Cantor Fitzgerald downgraded Asensus Surgical from Overweight to Neutral
Cantor Fitzgerald initiated coverage of Asensus Surgical with a rating of Overweight and set a new price target of $1.50
Stifel initiated coverage of Asensus Surgical with a rating of Buy and set a new price target of $1.50
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To access the live audi
RESEARCH TRIANGLE PARK, N.C., March 15, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Friday. The Dow traded up 0.12% to 38,931.98 while the NASDAQ fell 0.09% to 17,156.98. The S&P 500 also rose, gaining, 0.11% to 5,359.05. Check This Out: Vail Resorts, DocuSign And 3 Stocks To Watch Heading Into Friday Leading and Lagging SectorsFinancial shares climbed by 0.7% on Friday. In trading on Friday, real estate shares dipped by 0.8%. Top Headline The total number of active U.S. oil rigs fell by four to 492 rigs this week, Baker Hughes Inc reported. Equities Trading UP Venus Concept Inc. (NASDAQ:VERO) shares shot up 74% to $1.0776 on
Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing two new board members, Elizabeth Kwo, MD and Kevin Hobert, effective immediately. "We are delighted to welcome two accomplished industry veterans to our Board of Directors, each of whom bring highly relevant and unique skills to the organization that complement our current leadership team in an impactful way," said Paul LaViolette, Chairman of the Board of Asensus Surgical. "Liz has a tremendous track record of bringing innovative healthcare t
BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of Cocrystal extend their deepest condolences to the Wilcox family and express their gratitude for Gary's contributions to Cocrystal and to human health. The Cocrystal Board of Directors has designated Sam Lee, Ph.D., President, and James Martin, CFO, to share the CEO responsibilities while seeking a successor for the position. Roger Kornberg, Ph.D., Cocrystal co-founder, Chief Scientist, Director and
RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the "Merger") with the KARL STORZ Group ("KARL STORZ"). The transaction was completed following approval by the Asensus Surgical stockholders. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a sub
RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the second quarter 2024. Recent Highlights Announced a definitive merger agreement (the "Merger Agreement") with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company. Under the Merger Agreement, KARL STORZ will acquire all of the outstanding shares of Asensus Surgical for $0.35 per share in cash (the "Merger")Leading independent proxy advisory firms,
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately
SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)
SC 13G/A - ASENSUS SURGICAL, INC. (0000876378) (Subject)
SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)